An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. Their findings are reported online today in Nature Genetics.
The investigators identified STAG2 as one of the most commonly mutated genes in bladder cancer, particularly in tumors that do not spread. The finding suggests that checking the status of the gene may help identify patients who might do unusually well following cancer treatment, says the study's senior investigator, cancer geneticist Todd Waldman, MD, PhD, a professor of oncology at Georgetown Lombardi.
"Most bladder cancers are superficial tumors that have not spread to other parts of the body, and can therefore be easily treated and cured. However, a small fraction of these superficial tumors will recur and metastasize even after treatment," he says.
Because clinicians have been unable to definitively identify those potentially lethal cancers, all bladder cancers patients—after surgery to remove tumors—must undergo frequent endoscopic examinations of their bladder to look for signs of recurrence, says Waldman. This procedure, called cystoscopy, can be uncomfortable and is expensive.
"Our data show that STAG2 is one of the earliest initiating gene mutations in 30-40 percent of superficial or 'papillary-type' bladder tumors, and that these tumors are unlikely to recur," says David Solomon, MD, PhD, a lead author on the study. Solomon is a graduate of the Georgetown MD/PhD program and is currently a pathology resident at the University of California, San Francisco.
"We have developed a simple test for pathologists to easily assess the STAG2 status of these tumors, and are currently performing a larger study to determine if this test should enter routine clinical use for predicting the likelihood that a superficial bladder cancer will recur," Solomon says.
For the study, the researchers examined 2,214 human tumors from virtually all sites of the human body for STAG2 inactivation and found that STAG2 was most commonly inactivated in bladder cancer, the fifth most common human cancer. In follow up work, they found that 36 percent of low risk bladder cancers—those that never invaded the bladder muscle or progressed—had mutated STAG2. That suggests that testing the STAG2 status of the cancer could help guide clinical care, Waldman says. "A positive STAG2 mutation could mean that patient is at lower risk of recurrence."
The researchers also found that 16 percent of the bladder cancers that did spread, or metastasize, had mutated STAG2.
STAG2 mutations have been found in a number of cancers, and this finding in bladder cancer adds new information, he says.
Explore further: Radiotherapy could spare bladder cancer patients surgery
More information: Frequent Truncating Mutations of STAG2 in Bladder Cancer, DOI: 10.1038/ng.2800
Medical Xpress on facebook
Related Stories
Mutant gene identified that causes abnormal chromosome count, leading to cancer
Aug 18, 2011
Cells with too few or too many chromosomes have long been known to be a hallmark of cancer — but the cause of this abnormal number of chromosomes has been little understood. Now, in the August 19th issue of Science, resear ...
Radiotherapy could spare bladder cancer patients surgery
Oct 01, 2013
Radiotherapy is an effective treatment for aggressive bladder cancer and could spare patients surgery that removes the whole bladder, according to a study published in this month's International Journal of ...
Certain bladder-cancer patients may be at high risk of disease recurrence despite bladder removal
May 07, 2013
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.
Little molecule makes big difference in bladder cancer metastasis
Apr 09, 2013
In order to kill, bladder cancer must metastasize, most commonly to the lung – what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University ...
Bladder cancer recurrence and mortality could decline with better treatment compliance
Jun 05, 2013
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce ...
Recommended for you
Four genetic variants linked to esophageal cancer and Barrett's esophagus
3 seconds ago
An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased ...
Database of disease genes shows potential drug therapies
5 seconds ago
Researchers at Washington University School of Medicine in St. Louis have created a massive online database that matches thousands of genes linked to cancer and other diseases with drugs that target those ...
Non-infiltrating bladder cancer exome sequenced
6 seconds ago
Bladder cancer represents a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded every year, one of the highest rates in the world. The majority of these ...
On the lookout for the genes behind disease
Oct 11, 2013
Today's information age has provided the tools for biology to yield huge numbers of DNA sequences from many different species. Modern technology has made DNA sequencing simpler, less expensive and more reliable ...
Previously unstudied gene is essential for normal nerve development
Oct 10, 2013
Our ability to detect heat, touch, tickling and other sensations depends on our sensory nerves. Now, for the first time, researchers at Albert Einstein College of Medicine of Yeshiva University have identified ...
Super-enhancers seen as 'Rosetta Stone' for dialog between genes and disease
Oct 10, 2013
Having recently discovered a set of powerful gene regulators that control cell identity in a few mouse and human cell types, Whitehead Institute scientists are now showing that these regulators—which they named "super-enhancers"—act ...
User comments
© Medical Xpress 2011-2013, Phys.org network
An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. Their findings are reported online today in Nature Genetics.
The investigators identified STAG2 as one of the most commonly mutated genes in bladder cancer, particularly in tumors that do not spread. The finding suggests that checking the status of the gene may help identify patients who might do unusually well following cancer treatment, says the study's senior investigator, cancer geneticist Todd Waldman, MD, PhD, a professor of oncology at Georgetown Lombardi.
"Most bladder cancers are superficial tumors that have not spread to other parts of the body, and can therefore be easily treated and cured. However, a small fraction of these superficial tumors will recur and metastasize even after treatment," he says.
Because clinicians have been unable to definitively identify those potentially lethal cancers, all bladder cancers patients—after surgery to remove tumors—must undergo frequent endoscopic examinations of their bladder to look for signs of recurrence, says Waldman. This procedure, called cystoscopy, can be uncomfortable and is expensive.
"Our data show that STAG2 is one of the earliest initiating gene mutations in 30-40 percent of superficial or 'papillary-type' bladder tumors, and that these tumors are unlikely to recur," says David Solomon, MD, PhD, a lead author on the study. Solomon is a graduate of the Georgetown MD/PhD program and is currently a pathology resident at the University of California, San Francisco.
"We have developed a simple test for pathologists to easily assess the STAG2 status of these tumors, and are currently performing a larger study to determine if this test should enter routine clinical use for predicting the likelihood that a superficial bladder cancer will recur," Solomon says.
For the study, the researchers examined 2,214 human tumors from virtually all sites of the human body for STAG2 inactivation and found that STAG2 was most commonly inactivated in bladder cancer, the fifth most common human cancer. In follow up work, they found that 36 percent of low risk bladder cancers—those that never invaded the bladder muscle or progressed—had mutated STAG2. That suggests that testing the STAG2 status of the cancer could help guide clinical care, Waldman says. "A positive STAG2 mutation could mean that patient is at lower risk of recurrence."
The researchers also found that 16 percent of the bladder cancers that did spread, or metastasize, had mutated STAG2.
STAG2 mutations have been found in a number of cancers, and this finding in bladder cancer adds new information, he says.
Explore further: Radiotherapy could spare bladder cancer patients surgery
More information: Frequent Truncating Mutations of STAG2 in Bladder Cancer, DOI: 10.1038/ng.2800
Medical Xpress on facebook
Related Stories
Mutant gene identified that causes abnormal chromosome count, leading to cancer
Aug 18, 2011
Cells with too few or too many chromosomes have long been known to be a hallmark of cancer — but the cause of this abnormal number of chromosomes has been little understood. Now, in the August 19th issue of Science, resear ...
Radiotherapy could spare bladder cancer patients surgery
Oct 01, 2013
Radiotherapy is an effective treatment for aggressive bladder cancer and could spare patients surgery that removes the whole bladder, according to a study published in this month's International Journal of ...
Certain bladder-cancer patients may be at high risk of disease recurrence despite bladder removal
May 07, 2013
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.
Little molecule makes big difference in bladder cancer metastasis
Apr 09, 2013
In order to kill, bladder cancer must metastasize, most commonly to the lung – what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University ...
Bladder cancer recurrence and mortality could decline with better treatment compliance
Jun 05, 2013
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce ...
Recommended for you
Four genetic variants linked to esophageal cancer and Barrett's esophagus
3 seconds ago
An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased ...
Database of disease genes shows potential drug therapies
5 seconds ago
Researchers at Washington University School of Medicine in St. Louis have created a massive online database that matches thousands of genes linked to cancer and other diseases with drugs that target those ...
Non-infiltrating bladder cancer exome sequenced
6 seconds ago
Bladder cancer represents a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded every year, one of the highest rates in the world. The majority of these ...
On the lookout for the genes behind disease
Oct 11, 2013
Today's information age has provided the tools for biology to yield huge numbers of DNA sequences from many different species. Modern technology has made DNA sequencing simpler, less expensive and more reliable ...
Previously unstudied gene is essential for normal nerve development
Oct 10, 2013
Our ability to detect heat, touch, tickling and other sensations depends on our sensory nerves. Now, for the first time, researchers at Albert Einstein College of Medicine of Yeshiva University have identified ...
Super-enhancers seen as 'Rosetta Stone' for dialog between genes and disease
Oct 10, 2013
Having recently discovered a set of powerful gene regulators that control cell identity in a few mouse and human cell types, Whitehead Institute scientists are now showing that these regulators—which they named "super-enhancers"—act ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment